Partnership Opportunities

Why Partner With Us?

The 5th Neuropsychiatric and Psychedelics Drug Development Summit will give you the prospect of promoting your product to the key experts pushing forwards research in therapeutics for mental health disorders.

As more potential therapeutics move closer towards clinical trials there has never been a more valuable opportunity to merge ideas and capabilities in the psychiatric drug development space.

Partner with us to network one-on-one with stakeholders in this intimate forum of engaged specialists.  Ongoing challenges with niche assays, imaging, psychedelic services, digital platforms and more are still faced by leading industry members. Don’t miss out on this unique opening to understand where their issues lie and present your innovative solutions directly to decision makers.

We understand that each business will require tailored packages to suit their needs from presentations on the main agenda, exhibition booths, to drinks receptions, the choices are endless for bringing your company to the forefront of the industry.

We have limited opportunities available to maintain the industry focus of the event, make sure to be one of the select few and act quickly to reserve your place. Contact us today to learn how we can help you achieve your business goals faster and more effectively online at

Find Out More: Contact Us

Processed with VSCO with b5 preset

George O'Connor

Partnership Director

Phone: (+1) 617 455 4188


Partner Testimonials:

“Very well organized conference with exceptional speakers. Well represented across Pharma/Biotech/Academics/Service providers.”
- Linda Hedley, Business Development Consultant, SRI International

“I liked the conference and the chance to interact with many of the sponsors.”
- David Walling, CEO, CNS Network LLC

“This cozy format of the meeting allowed us to meet all the attendees and to have strong interactions.”
- Naert Gaelle, COO, CILcare

“This summit was concise enough to meet with industrial experts closely and exchange information.”
- Mitsuyuki Mickey Matsumoto, Executive Director, Research Unit Head, Astellas Pharma Inc.